The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Molecular Biomarkers for the Early Detection of Ovarian Cancer
Open accessAbstract
Ovarian cancer is the deadliest gynecological cancer, leading to over 152,000 deaths each year. A late diagnosis is the primary factor causing a poor prognosis of ovarian cancer and often occurs due to a lack of specific symptoms and effective biomarkers for an early detection. Currently, cancer antigen 125 (CA125) is the most widely used biomarker for ovarian cancer detection, but this approach is limited by a low specificity. In recent years, multimarker panels have been developed by combining molecular biomarkers such as human epididymis secretory protein 4 (HE4), ultrasound results, or menopausal status to improve the diagnostic efficacy. The risk of ovarian malignancy algorithm (ROMA), the risk of malignancy index (RMI), and OVA1 assays have also been clinically used with improved sensitivity and specificity. Ongoing investigations into novel biomarkers such as autoantibodies, ctDNAs, miRNAs, and DNA methylation signatures continue to aim to provide earlier detection methods for ovarian cancer. This paper reviews recent advancements in molecular biomarkers for the early detection of ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
JACOBS, I., ORAM, D., FAIRBANKS, J., TURNER, J., FROST, C., & GRUDZINSKAS, J. G. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb02448.x · Cited by 962
Moore, R. G., McMeekin, D. S., Brown, A. K., DiSilvestro, P., Miller, M. C., Allard, W. J., Gajewski, W., Kurman, R., Bast, R. C., & Skates, S. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.031 · Cited by 875
Menon, U., Gentry-Maharaj, A., Burnell, M., Singh, N., Ryan, A., Karpinskyj, C., Carlino, G., Taylor, J., Massingham, S. K., Raikou, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00731-5 · Cited by 730
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
Tingulstad, S., Hagen, B., Skjeldestad, F. E., Onsrud, M., Kiserud, T., Halvorsen, T., & Nustad, K. (1996) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1996.tb09882.x · Cited by 349
Characterization of serum biomarkers for detection of early stage ovarian cancer
Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K., Reddy, S., & Farias‐Eisner, R. (2005) · PROTEOMICS · doi:10.1002/pmic.200500093 · Cited by 311
ctDNA as a cancer biomarker: A broad overview
Pessoa, L. S., Heringer, M., & Ferrer, V. P. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103109 · Cited by 298
Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial
Partridge, E., Kreimer, A. R., Greenlee, R. T., Williams, C., Xu, J.-L., Church, T. R., Kessel, B., Johnson, C. C., Weissfeld, J. L., Isaacs, C., et al. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31819cda77 · Cited by 258
THE RISK-OF-MALIGNANCY INDEX TO EVALUATE POTENTIAL OVARIAN CANCERS IN LOCAL HOSPITALS
Tingulstad, S., Hagen, B., Skjeldestad, F. E., Halvorsen, T., Nustad, K., & Onsrud, M. (1999) · Obstetrics & Gynecology · doi:10.1097/00006250-199903000-00028 · Cited by 235
Effectiveness of a Multivariate Index Assay in the Preoperative Assessment of Ovarian Tumors
Ueland, F. R., Desimone, C. P., Seamon, L. G., Miller, R. A., Goodrich, S., Podzielinski, I., Sokoll, L., Smith, A., van Nagell, J. R., & Zhang, Z. (2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31821b5118 · Cited by 231
Bingle, L., Cross, S. S., High, A. S., Wallace, W. A., Rassl, D. M., Yuan, G., Hellström, I., Campos, M., & Bingle, C. D. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-61 · Cited by 201
The Accuracy of Risk Scores in Predicting Ovarian Malignancy: A Systematic Review
Geomini, P., Kruitwagen, R., Bremer, G. L., Cnossen, J., & Mol, B. W. J. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318195ad17 · Cited by 184
Emerging roles for folate receptor FOLR1 in signaling and cancer
Nawaz, F. Z., & Kipreos, E. T. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.12.003 · Cited by 183
HE4 as a biomarker for ovarian and endometrial cancer management
Li, J., Dowdy, S., Tipton, T., Podratz, K., Lu, W.-G., Xie, X., & Jiang, S.-W. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.39 · Cited by 171
TP53 Mutations in Breast and Ovarian Cancer
Silwal-Pandit, L., Langerød, A., & Børresen-Dale, A.-L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026252 · Cited by 167
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
Jacob, F., Meier, M., Caduff, R., Goldstein, D., Pochechueva, T., Hacker, N., Fink, D., & Heinzelmann-Schwarz, V. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.02.022 · Cited by 165
Scaletta, G., Plotti, F., Luvero, D., Capriglione, S., Montera, R., Miranda, A., Lopez, S., Terranova, C., De Cicco Nardone, C., & Angioli, R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1360138 · Cited by 163
Saldova, R., Wormald, M. R., Dwek, R. A., & Rudd, P. M. (2008) · Disease Markers · doi:10.1155/2008/601583 · Cited by 162
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors
Timmerman, D., Planchamp, F., Bourne, T., Landolfo, C., du Bois, A., Chiva, L. M., Cibula, D., Concin, N., Fischerová, D., Froyman, W., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2021-002565 · Cited by 158
Yamamoto, Y., Yamada, R., Oguri, H., Maeda, N., & Fukaya, T. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.02.048 · Cited by 154
CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients
Høgdall, E. V. S., Christensen, L. H., Kjær, S. K., Blaakær, J., Kjærbye‐Thygesen, A., Gayther, S. A., Jacobs, I. J., & Høgdall, C. K. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.09.028 · Cited by 144
Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay
Bristow, R. E., Smith, A., Zhang, Z., Chan, D. W., Crutcher, G., Fung, E. T., & Munroe, D. G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.11.022 · Cited by 137
Lu, K. H., Skates, S. J., Hernandez, M. A., Bedi, D. G., Bevers, T. B., Leeds, L. J., Moore, R. G., Granai, C. O., Harris, S., Newland, W., et al. (2013) · Cancer · doi:10.1002/cncr.28183 · Cited by 136
CALSTER, B. V., Valentin, L., Froyman, W., Landolfo, C., Ceusters, J., Testa, A. C., Wynants, L., Sladkevicius, P., Holsbeke, C. V., Domali, E., et al. (2020) · BMJ · doi:10.1136/bmj.m2614 · Cited by 133
AOCS Study Group, Köbel, M., Madore, J., Ramus, S. J., Clarke, B. A., Pharoah, P. D. P., Deen, S., Bowtell, D. D. L., Odunsi, K. O., Menon, U., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.567 · Cited by 118
Autoantibody Signature for the Serologic Detection of Ovarian Cancer
Anderson, K. S., Cramer, D. W., Sibani, S., Wallstrom, G. L., Wong, J., Park, J. K., Qiu, J., Vitonis, A. F., & LaBaer, J. (2014) · Journal of Proteome Research · doi:10.1021/pr500908n · Cited by 116
Russell, M. R., Graham, C., D’Amato, A., Gentry‐Maharaj, A., Ryan, A., Kalsi, J., Ainley, C., Whetton, A. D., Menon, U., Jacobs, I. J., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.199 · Cited by 111
Karlsen, M. A., Høgdall, E. V. S., Christensen, I. J., Borgfeldt, C., Kalapotharakos, G., Dubská, L. Z., Chovanec, J., Lok, C. A. R., Stiekema, A., Mutz‐Dehbalaie, I., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.021 · Cited by 107
Kurosaki, A., Hasegawa, K., Kato, T., Abe, K., Hanaoka, T., Miyara, A., O'Shannessy, D. J., Somers, E. B., Yasuda, M., Sekino, T., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29937 · Cited by 105
Terry, K. L., Schöck, H., Fortner, R. T., Hüsing, A., Fichorova, R. N., Yamamoto, H. S., Vitonis, A. F., Johnson, T., Overvad, K., Tjønneland, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0316 · Cited by 105
Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients
Leung, F., Dimitromanolakis, A., Kobayashi, H., Diamandis, E. P., & Kulasingam, V. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.03.010 · Cited by 100
Improved early detection of ovarian cancer using longitudinal multimarker models
Whitwell, H. J., Worthington, J., Blyuss, O. B., Gentry‐Maharaj, A., Ryan, A., Gunu, R., Kalsi, J., Menon, U., Jacobs, I. J., Zaikin, A. A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0718-9 · Cited by 98
Differential Methylation Profile of Ovarian Cancer in Tissues and Plasma
Melnikov, A. A., Scholtens, D. M., Godwin, A. K., et al. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080072 · Cited by 96
The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass
Chan, K. K. L., Chen, C., Nam, J., Ochiai, K., Wilailak, S., Choon, A. T., Sabaratnam, S., Hebbar, S., Sickan, J., Schodin, B. A., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.09.034 · Cited by 85
Self-citationSkates, S. J. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318256488a · Cited by 80
Diagnostic performance of CA 125, HE 4, and risk of Ovarian Malignancy Algorithm for ovarian cancer
Kim, B., Park, Y., Kim, B., et al. (2018) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22624 · Cited by 80
Zhu, Z., Zhu, Z., 陈兆军, Wang, M., Zhang, M., chen, Y., Yang, X., Zhou, C., 刘玉华, Zhang, L., et al. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-00961-x · Cited by 69
Morgan, S. R., Whiteley, J. L., Donald, E. L., Smith, J. C., Eisenberg, M. T., Kallam, E., & Kam-Morgan, L. N. W. (2012) · Clinical Medicine Insights Pathology · doi:10.4137/cpath.s8798 · Cited by 67
Autoantibody biomarkers for the detection of serous ovarian cancer
Katchman, B. A., Chowell, D., Wallstrom, G. L., Vitonis, A. F., LaBaer, J., Cramer, D. W., & Anderson, K. S. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.005 · Cited by 67
Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer
Gong, G., Lin, T., & Yuan, Y. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00632-9 · Cited by 66
Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125
Bayoumy, S., Hyytiä, H., Leivo, J., Talha, S. M., Huhtinen, K., POUTANEN, M. H., Hynninen, J., Perheentupa, A. H., Lamminmäki, U., Gidwani, K., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01191-x · Cited by 63
Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer
Yang, W., Gentry‐Maharaj, A., Simmons, A. R., Ryan, A., Fourkala, E.-O., Lü, Z., Baggerly, K., Zhao, Y., Lu, K. H., Bowtell, D. D. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0284 · Cited by 62
Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer
Mukama, T., Fortner, R. T., Katzke, V. A., Hynes, L. C., Petrera, A., Hauck, S. M., Johnson, T., Schulze, M. B., Schiborn, C., Rostgaard‐Hansen, A. L., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01697-z · Cited by 62
Serum exosomal microRNA-34a as a potential biomarker in epithelial ovarian cancer
Maeda, K., Sasaki, H., Ueda, S., Miyamoto, S., Terada, S., Konishi, H., Kogata, Y., Ashihara, K., Fujiwara, S., Tanaka, Y., et al. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00648-1 · Cited by 61
Glycoforms of CA125 antigen as a possible cancer marker
Jankovic, M. M., & Milutinovic, B. S. (2008) · Cancer Biomarkers · doi:10.3233/cbm-2008-4104 · Cited by 59 · cited 1×
“The carbohydrate side chains of glycoproteins can be truncated or aberrant in tumor tissue due to different glycosylation processes that occur during the oncogenic transformation [30].”
BackgroundExosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
Chen, Z., Liang, Q., Zeng, H., Zhao, Q., Guo, Z., Zhong, R., Xie, M., Cai, X., Su, J., He, Z., et al. (2020) · Journal of Cancer · doi:10.7150/jca.48531 · Cited by 55
Ma, Y., Wang, X., Qiu, C., Qin, J., Wang, K., Sun, G., Jiang, D., Li, J., Wang, L., Shi, J., et al. (2020) · Cancer Science · doi:10.1111/cas.14732 · Cited by 55
James, N. E., Chichester, C. O., & Ribeiro, J. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00124 · Cited by 52
Diagnostic value of HE4 in ovarian cancer: A meta-analysis
Huang, J., Chen, J., & Huang, Q. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.10.008 · Cited by 52
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
Havrilesky, L. J., Sanders, G. D., Kulasingam, S., & Myers, E. R. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.07.006 · Cited by 51
Clinical value of ROMA index in diagnosis of ovarian cancer: meta-analysis
Cui, R., Wang, Y., Li, Y., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s199400 · Cited by 51
Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients
Diamandis, E. P., Borgoño, C. A., Scorilas, A., Harbeck, N., Dorn, J., & Schmitt, M. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.04.009 · Cited by 48
Funston, G., Mounce, L. T. A., Price, S. J., Rous, B., Crosbie, E. J., Hamilton, W. T., & Walter, F. M. (2021) · British Journal of General Practice · doi:10.3399/bjgp.2020.0859 · Cited by 47
Barr, C. E., Funston, G., Jeevan, D. N., Sundar, S. S., Mounce, L. T. A., & Crosbie, E. J. (2022) · Cancers · doi:10.3390/cancers14092124 · Cited by 46
Lycke, M., Ulfenborg, B., Lauesgaard, J. M., Kristjánsdóttir, B., & Sundfeldt, K. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0510 · Cited by 43
Li, B., Pu, K., Ge, L., & Wu, X. (2019) · Gene · doi:10.1016/j.gene.2019.143993 · Cited by 41
Flores, C. P., García-Vázquez, R., Rincón, D. G., Ruíz‐García, E., de la Vega, H. A., Marchat, L. A., Salinas-Vera, Y. M., & López‐Camarillo, C. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3948 · Cited by 40
Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer
Qiu, C., Duan, Y., Wang, B., Shi, J., Wang, P., Ye, H., Dai, L., Zhang, J., & Wang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698312 · Cited by 38
Jiang, S., Chen, H.-B., Dowdy, S. C., Fu, A., Attewell, J. R., Kalogera, E., Drapkin, R., Podratz, K. C., Broaddus, R. R., & Li, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122655 · Cited by 36
Hada, A., Han, L., Chen, Y., et al. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00643-6 · Cited by 36
Methods for Identification of CA125 from Ovarian Cancer Ascites by High Resolution Mass Spectrometry
Weiland, F., Fritz, K., Oehler, M. K., & Hoffmann, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089942 · Cited by 34
Rowswell-Turner, R. B., Singh, R. K., Urh, A., Yano, N., Kim, K., Khazan, N., Pandita, R., Sivagnanalingam, U., Hovanesian, V., James, N. E., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000281 · Cited by 34
The role of transvaginal ultrasound in screening for ovarian cancer
Campbell, S. C., & Gentry‐Maharaj, A. (2018) · Climacteric · doi:10.1080/13697137.2018.1433656 · Cited by 33
Shin, K., Kim, H. H., Kwon, B. S., et al. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2020.40.1.40 · Cited by 33
Gentry‐Maharaj, A., Blyuss, O. B., Ryan, A., Burnell, M., Karpinskyj, C., Gunu, R., Kalsi, J., Dawnay, A., Mariño, I. P., Manchanda, R., et al. (2020) · Cancers · doi:10.3390/cancers12071931 · Cited by 33
Bressan, A., Bozzo, F., Maggi, C. A., & Binaschi, M. (2013) · Disease Markers · doi:10.1155/2013/917898 · Cited by 30
Gidwani, K., Nadeem, N., Huhtinen, K., Kekki, H., Heinosalo, T., Hynninen, J., Perheentupa, A. H., POUTANEN, M. H., Carpén, O., Pettersson, K. S. I., et al. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.028266 · Cited by 27
The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis
Lu, Y., & Li, L. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211043784 · Cited by 27
Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors
Carreras‐Dieguez, N., Glickman, A. G., Munmany, M., Casanovas, G., Agustí, N., Díaz‐Feijoó, B., Saco, A., Sánchez, B., Gaba, L., Ángeles, M. A., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12010226 · Cited by 27
Anastasi, E., Manganaro, L., Granato, T., Panici, P. B., Frati, L., & Porpora, M. G. (2013) · Disease Markers · doi:10.1155/2013/984641 · Cited by 26
Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative
Dunton, C. J., Hutchcraft, M. L., Bullock, R. G., Northrop, L. E., & Ueland, F. R. (2021) · Diagnostics · doi:10.3390/diagnostics11081440 · Cited by 26
Zhu, C., Zhang, N., Zhong, A., Xiao, K., Lu, R., & Guo, L. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.11.018 · Cited by 26
State of the science: Contemporary front-line treatment of advanced ovarian cancer
Hinchcliff, E., Westin, S. N., & Herzog, T. J. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.04.021 · Cited by 26
Wang, Y., Ren, S., Jiang, W., Lu, J., Zhang, X., Li, X., Cao, R., & Xu, C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8053 · Cited by 25
Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer
Jain, S., Nadeem, N., Ulfenborg, B., Mäkelä, M., Ruma, S. A., Terävä, J., Huhtinen, K., Leivo, J., Kristjánsdóttir, B., Pettersson, K. S. I., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34111 · Cited by 25
Hasenburg, A., Eichkorn, D., Vosshagen, F., Obermayr, E., Geroldinger, A., Zeillinger, R., & Bossart, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08682-y · Cited by 23
Qiao, L., Chen, X., Xi, X., Chen, X., Zhang, P., Dong, H., Wu, X., & Chen, X. (2020) · Medicine · doi:10.1097/md.0000000000023329 · Cited by 22
Bartoletti, M., Musacchio, L., Giannone, G., Tuninetti, V., Bergamini, A., Scambia, G., Lorusso, D., Valabrega, G., Mangili, G., Puglisi, F., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102298 · Cited by 22
Ngu, S., Chai, Y. K., Choi, K. M., Leung, T. W., Li, J., Kwok, S. T., Chu, M. M. Y., Tse, K. Y., Cheung, V. Y. T., Ngan, H., et al. (2022) · Cancers · doi:10.3390/cancers14030810 · Cited by 22
Self-citationWang, P., Qin, J., Ye, H., Li, L., Wang, X., & Zhang, J. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27497 · Cited by 21
Minář, L., Felsinger, M., Čermáková, Z., et al. (2017) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12371 · Cited by 19
Current First-line Therapy for Ovarian Cancer: A Comprehensive Review
Pierce, S. R., & Clark, L. H. (2018) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000613 · Cited by 17
Schuster-Little, N., Fritz-Klaus, R., Etzel, M. R., Patankar, N., Javeri, S., Patankar, M. S., & Whelan, R. J. (2020) · The Analyst · doi:10.1039/d0an01701a · Cited by 17
Ovarian cancer screening in the general population
Mathis, J., Jellouli, M. A., Sabiani, L., Fest, J., Blache, G., & Mathevet, P. (2019) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2019-0038 · Cited by 16
Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer
Duan, Y., Cui, C., Qiu, C., Sun, G., Wang, X., Wang, P., Ye, H., Dai, L., & Shi, J. (2022) · Disease Markers · doi:10.1155/2022/6657820 · Cited by 12
Xin, B., Ji, K., Liu, Y.-S., & Zhao, X. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00368-3 · Cited by 10
BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer
Pilyugin, M., Ratajska, M., Stukan, M., Concin, N., Zeillinger, R., & Irminger‐Finger, I. (2021) · Genes · doi:10.3390/genes12070969 · Cited by 7
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Metadata
- Authors
- Zhang, R., Siu, M. K. Y., Ngan, H. Y. S., & Chan, K. K. L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-10-10
- Volume
- 23
- Issue
- 19
- Pages
- 12041
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4304136151
- Cited by
- 283
- References
- 92
- FWCI
- 40.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.